Antimicrobial Stewardship Improves Outcomes for MRSA

WEDNESDAY, Dec. 30, 2015 (HealthDay News) — For patients receiving antimicrobial injections targeting methicillin-resistant Staphylococcus aureus (MRSA), implementation of an antimicrobial stewardship program that includes daily review of prescriptions is associated with improved clinical outcomes, according to a study published online Dec. 18 in the Journal of Clinical Pharmacy and Therapeutics.

Takashi Niwa, Ph.D., from Gifu University Hospital in Japan, and colleagues conducted a single-center retrospective study to examine the effects of an antimicrobial stewardship program targeting MRSA in patients receiving pathogen-specific antibiotics. A team was assembled to implement antimicrobial stewardship; daily reviews of prescriptions were conducted within 24 hours after initiation of therapy.

The researchers found that implementation of daily review correlated with a significant reduction in the time to administer effective antimicrobials (median number of days, three versus zero; P < 0.001) and with a significant elevation in the rate of de-escalation (47.1 versus 96.2 percent; P < 0.001). After the intervention, there was a significant reduction in 60-day clinical failure associated with gram-positive bacterial infection (33.3 versus 17.6 percent; P = 0.007).

“Daily review of administration of antimicrobials targeting MRSA was highly effective in improving clinical outcomes by optimizing early antimicrobial therapy,” the authors write.

Abstract
Full Text (subscription or payment may be required)